Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Icecure Medical (ICCM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ICCM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2.59
1 Year Target Price $2.59
| 1 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -32.09% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 81.70M USD | Price to earnings Ratio - | 1Y Target Price 2.59 |
Price to earnings Ratio - | 1Y Target Price 2.59 | ||
Volume (30-day avg) 3 | Beta 2.35 | 52 Weeks Range 0.47 - 1.63 | Updated Date 08/29/2025 |
52 Weeks Range 0.47 - 1.63 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.27 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-13 | When - | Estimate -0.06 | Actual 0.12 |
Profitability
Profit Margin - | Operating Margin (TTM) -644.76% |
Management Effectiveness
Return on Assets (TTM) -76.4% | Return on Equity (TTM) -230.8% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 78682542 | Price to Sales(TTM) 29.31 |
Enterprise Value 78682542 | Price to Sales(TTM) 29.31 | ||
Enterprise Value to Revenue 28.23 | Enterprise Value to EBITDA -2.63 | Shares Outstanding 68651696 | Shares Floating 37894170 |
Shares Outstanding 68651696 | Shares Floating 37894170 | ||
Percent Insiders 40.6 | Percent Institutions 0.36 |
Upturn AI SWOT
Icecure Medical
Company Overview
History and Background
IceCure Medical was founded in 2006 and is headquartered in Caesarea, Israel. The company focuses on developing cryoablation technology for tumor treatment. It has evolved from early research to commercializing its ProSense system and expanding its clinical applications.
Core Business Areas
- Cryoablation Technology: Development and commercialization of cryoablation systems for minimally invasive tumor treatment.
Leadership and Structure
The leadership team consists of a CEO, CFO, and other key executives overseeing research, development, and commercialization. The organizational structure is designed to support innovation and market penetration in the medical device sector.
Top Products and Market Share
Key Offerings
- ProSense System: A liquid nitrogen-based cryoablation system used for destroying tumors, particularly in breast, kidney, and lung cancers. The device lacks significant market share currently, but it competes with minimally invasive surgical procedures and other ablation technologies. Competitors include Medtronic (MDT) and Boston Scientific (BSX), which produce radiofrequency ablation devices and Johnson & Johnson (JNJ) through its Ethicon surgical division
Market Dynamics
Industry Overview
The cryoablation market is growing due to increasing demand for minimally invasive cancer treatments and technological advancements in ablation techniques. Key drivers include an aging population and rising cancer incidence rates.
Positioning
IceCure Medical is positioned as an innovator in cryoablation technology, focusing on providing effective and minimally invasive solutions. Its competitive advantage lies in its liquid nitrogen-based ProSense system that has the potential to offer better cooling and less recovery time.
Total Addressable Market (TAM)
The TAM for minimally invasive cancer treatment is estimated in billions of dollars, encompassing a wide range of tumors and treatment settings. IceCure Medical is positioned to capture a share of this market by focusing on specific applications like breast and kidney cancer.
Upturn SWOT Analysis
Strengths
- Innovative cryoablation technology
- Minimally invasive treatment option
- Potential for reduced recovery time
- Targeting specific cancer types
Weaknesses
- Limited market share
- Reliance on a single product (ProSense)
- Requires regulatory approvals and clinical data
- Small company size compared to larger competitors
Opportunities
- Expanding applications of cryoablation
- Partnerships with hospitals and clinics
- Geographic expansion into new markets
- Further clinical trials to demonstrate efficacy
Threats
- Competition from established medical device companies
- Regulatory hurdles and delays
- Technological advancements by competitors
- Pricing pressures and reimbursement challenges
Competitors and Market Share
Key Competitors
- MDT
- BSX
- JNJ
Competitive Landscape
IceCure Medical is a smaller player compared to its competitors. Its advantages include its innovative technology, but it faces challenges in scaling up production and distribution.
Growth Trajectory and Initiatives
Historical Growth: Historical growth requires access to financial data, which is not available in this format.
Future Projections: Future projections require access to analyst estimates, which is not available in this format.
Recent Initiatives: Recent initiatives include expanding clinical trials for ProSense and pursuing regulatory approvals in new markets.
Summary
IceCure Medical is a small company with innovative cryoablation technology, but it faces significant competition from larger, established medical device companies. The company's success depends on its ability to expand the clinical applications of ProSense, secure regulatory approvals, and establish strategic partnerships. Pricing pressures and reimbursement challenges in the medical device industry also pose potential risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Market research reports
- Financial news sources
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Icecure Medical
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-08-26 | CEO & Director Mr. Eyal Shamir | ||
Sector Healthcare | Industry Medical Devices | Full time employees 64 | Website https://www.icecure-medical.com |
Full time employees 64 | Website https://www.icecure-medical.com | ||
IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.